#United States #Chicago #Adcentrx #ADCs #AACR2025

Adcentrx Therapeutics to Present Innovative ADCs at AACR 2025

Adcentrx Therapeutics, a pioneering clinical-stage biotechnology firm, is gearing up to present their latest findings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago, Illinois. These presentations will emphasize the company's cutting-edge advancements in Antibody-Drug Conjugate (ADC) therapies, particularly focusing on their clinical-stage ADRX-0405 and preclinical ADRX-0134.

Breakthrough Presentations

The conference will feature both an oral presentation and a poster presentation, showcasing critical preclinical data that supports the distinct advantages of Adcentrx’s innovative ADC platforms. The clinical-stage ADC, ADRX-0405, is designed to target STEAP1, a protein associated with various cancers, including metastatic castration-resistant prostate cancer (mCRPC). Meanwhile, ADRX-0134 aims to combat lung and ovarian cancers, targeting NaPi2b with a unique approach.

Oral Presentation: ADRX-0405

During the oral session, Adcentrx will highlight the potential of ADRX-0405 as a first-in-class ADC against cancers that express STEAP1. This presentation is crucial as mCRPC and similar tumors often lack effective treatment options. Employing a modern topoisomerase inhibitor payload linked to a humanized IgG1 antibody, ADRX-0405 has demonstrated significant preclinical efficacy and a favorable safety profile in experimental models. The session is scheduled for April 27 from 3:25 to 3:40 PM CST, with abstract number 1159, under the theme of Antibody-Based Cancer Therapeutic Agents.

Poster Presentation: ADRX-0134

Following the oral presentation, Adcentrx will present a poster detailing the promising features of ADRX-0134. This preclinical ADC also leverages the company's advanced i-Conjugation® technology and incorporates the clinically validated AP052 tubulin inhibitor payload. This innovative design enhances the therapeutic window specifically for patients grappling with limited treatment options in lung and ovarian cancers. The poster is to be displayed on April 28 from 9:00 AM to 12:00 PM CST, with abstract number 1563, categorized under Antibody-Based Cancer Therapeutics.

The Technology Behind Adcentrx

Central to these advancements is Adcentrx's proprietary i-Conjugation® technology. This platform plays an integral role in the ADC design, employing stable conjugation chemistry alongside cleavable linkers to optimize payload delivery and improve therapeutic outcomes. By enhancing the stability and efficacy of ADCs, Adcentrx is setting a new standard for targeted cancer therapies.

Future Prospects

As a biotechnology company dedicated to revolutionizing cancer treatment, Adcentrx has laid the groundwork for multiple clinical-stage and preclinical ADC candidates. Each is strategically designed to address significant unmet medical needs in oncology. With presentations at AACR 2025, the company looks forward to sharing its extensive research and making strides in cancer therapeutics.

For those interested in the detailed findings and methodologies, Adcentrx welcomes attendees to engage at their booth during the conference. For further insights on their products and ongoing clinical trials, additional information can be accessed at Adcentrx Therapeutics or by referencing the clinical trial IDs available on ClinicalTrials.gov.

In conclusion, the upcoming AACR Annual Meeting serves as a pivotal platform for Adcentrx to showcase its innovative approaches in the fight against cancer, potentially transforming lives through enhanced treatment options. All eyes will be on Chicago as the biotech firm demonstrates the future of anticancer therapies.